Active, not recruitingPhase 3NCT04586231
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Studying Chromophobe renal cell carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Merck Sharp & Dohme LLC
- Principal Investigator
- Medical DirectorMerck Sharp & Dohme LLC
- Intervention
- Belzutifan(drug)
- Enrollment
- 747 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2027
Study locations (30)
- Ironwood Cancer & Research Centers ( Site 0077), Chandler, Arizona, United States
- Cedars Sinai Medical Center ( Site 0027), Los Angeles, California, United States
- UCLA Hematology/Oncology - Santa Monica ( Site 0048), Los Angeles, California, United States
- St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 0095), Orange, California, United States
- University of California, Irvine ( Site 0029), Orange, California, United States
- Providence Saint John's Health Center ( Site 0083), Santa Monica, California, United States
- Georgetown University Medical Center ( Site 0006), Washington D.C., District of Columbia, United States
- AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlandoc ( Site 0003), Orlando, Florida, United States
- Orlando Health, Inc. ( Site 0035), Orlando, Florida, United States
- University Cancer & Blood Center, LLC ( Site 0057), Athens, Georgia, United States
- Emory University Hospital ( Site 0012), Atlanta, Georgia, United States
- Rush University Medical Center ( Site 0040), Chicago, Illinois, United States
- Illinois Cancer Care, PC ( Site 0008), Peoria, Illinois, United States
- Parkview Cancer Institute ( Site 0088), Fort Wayne, Indiana, United States
- Norton Cancer Institute - St. Matthews ( Site 0065), Louisville, Kentucky, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Eisai Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04586231 on ClinicalTrials.govOther trials for Chromophobe renal cell carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07485114Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 InhibitorsDaniel Keizman
- RECRUITINGPHASE3NCT07227402A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)Merck Sharp & Dohme LLC
- RECRUITINGPHASE2NCT07233252Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic CancerTianjin Medical University Second Hospital
- RECRUITINGNANCT07171190Targeted Abdominal CT in Conjunction With Lung Cancer ScreeningUniversity of Cambridge
- RECRUITINGPHASE2NCT07050771Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer SurgeryThe Methodist Hospital Research Institute
- RECRUITINGPHASE2NCT06642220Ablative Radioembolization of Renal Cell Carcinoma TrialDerek W. Cool
- RECRUITINGNCT06889974Timing of Renal Replacement Therapy Initiation in Tumor Lysis SyndromeUniversity Hospital, Bordeaux
- ENROLLING BY INVITATIONNCT07307157Head-to-Head Evaluation of the Cancer Ontology Supervised Multimodal Orchestration (COSMO) AI System Versus Pathologist-Only ReviewHarvard Medical School (HMS and HSDM)